Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
NCT07207876 · View on ClinicalTrials.gov ↗
Study Summary
IMPAACT 2044 is a study to characterize the pharmacokinetics (PK) and safety of ceftriaxone and benzathine penicillin G during pregnancy. Up to 78 pregnant women receiving (1) ceftriaxone for indications other than syphilis or (2) benzathine penicillin G for treatment of syphilis from non-study clinical care providers will be enrolled at study sites located in the United States. Approximately 22 infants of pregnant participants receiving benzathine penicillin G will also be enrolled.
Conditions Studied
Interventions
- DRUG Ceftriaxon
- DRUG Benzathine penicillin G
Study Locations (9)
New York
- Site 5040, SUNY Stony Brook NICHD CRS — Stony Brook
- Site 5114, Bronx-Lebanon Hospital Center NICHD CRS — The Bronx
- Site 5013, Jacobi Med. Ctr. Bronx NICHD CRS — The Bronx
California
- Site 5048, USC - Maternal Child Adolescent/Adult Center — Los Angeles
- Site 5112, David Geffen School of Medicine at UCLA NICHD CRS — Los Angeles
Illinois
- Site 5083, Rush Univ. Cook County Hosp. Chicago NICHD CRS — Chicago
- Site 4001, Lurie Children's Hospital of Chicago (LCH) CRS — Chicago
Texas
- Site 5128, Baylor College of Medicine/Texas Children's Hospital NICHD CRS — Houston
Other
- Site 5129, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research CRS — San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2027-04-30 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07207876
The ClinicalTrials.gov registry entry for NCT07207876 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pregnancy appearing as the primary indexed condition, and to 2 interventions — of which Ceftriaxon is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07207876 reports 9 study locations spanning 5 distinct geographic areas — top geographies include New York, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07207876 about?
NCT07207876 is a clinical study titled "Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy". IMPAACT 2044 is a study to characterize the pharmacokinetics (PK) and safety of ceftriaxone and benzathine penicillin G during pregnancy. Up to 78 pregnant women receiving (1) ceftriaxone for indications other than syphilis or (2) benzathine penicillin G for treatment of syphilis from non-study clin...
What is the current status of trial NCT07207876?
This trial is currently recruiting. The enrollment target is 110 participants. The study started on 2026-02-16. Estimated completion is 2027-04-30.
What conditions does trial NCT07207876 study?
This clinical trial studies the following conditions: Pregnancy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07207876?
The interventions under investigation include: Ceftriaxon (DRUG), Benzathine penicillin G (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07207876?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07207876 being conducted?
This trial has 9 study locations across California, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.